Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Frustrated Roche Hopes NICE Will Eventually Back Kadcyla

This article was originally published in Scrip

Executive Summary

Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.


Related Content

NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer
NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
AbbVie's Humira Tops NHS Drug Spend List
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts